CenterBook Partners LP Buys 142,673 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Key Points

• CenterBook Partners LP increased its stake in Humacyte, Inc. by 11.1%, owning approximately 1,422,512 shares valued at $2.43 million.
• Humacyte's stock is currently trading at $2.21, down 4.3%, with a market cap of about $342.82 million and a price-to-earnings ratio of -3.20.
• Recent earnings results showed EPS of ($0.10), exceeding estimates, with analysts projecting an EPS of -1.27 for the current fiscal year.

CenterBook Partners LP increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 11.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,422,512 shares of the company's stock after buying an additional 142,673 shares during the period. CenterBook Partners LP owned 0.92% of Humacyte worth $2,425,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Raymond James Financial Inc. acquired a new stake in Humacyte in the 4th quarter worth about $377,000. KLP Kapitalforvaltning AS acquired a new stake in Humacyte in the 4th quarter worth about $99,000. LPL Financial LLC raised its stake in Humacyte by 3.5% in the 4th quarter. LPL Financial LLC now owns 529,992 shares of the company's stock worth $2,676,000 after purchasing an additional 18,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Humacyte in the 4th quarter worth about $2,189,000. Institutional investors own 44.71% of the company's stock.

Humacyte Trading Down 29.2%

HUMA traded down $0.73 during trading on Monday, reaching $1.76. 17,082,584 shares of the company's stock were exchanged, compared to its average volume of 3,882,617. Humacyte, Inc. has a one year low of $1.15 and a one year high of $7.73. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $272.23 million, a PE ratio of -2.51 and a beta of 1.90. The firm has a fifty day moving average price of $2.40 and a two-hundred day moving average price of $2.53.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.94 million. As a group, equities research analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HUMA has been the subject of several analyst reports. HC Wainwright initiated coverage on shares of Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 target price for the company. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday. Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Benchmark dropped their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.